Applied Therapeutics APLT Stock
Applied Therapeutics Price Chart
Applied Therapeutics APLT Financial and Trading Overview
| Applied Therapeutics stock price | 0.1 USD |
| Previous Close | 0 USD |
| Open | 0.1 USD |
| Bid | 0.09 USD x 200 |
| Ask | 0.11 USD x 1100 |
| Day's Range | 0.1 - 0.11 USD |
| 52 Week Range | 0.09 - 1.5 USD |
| Volume | 2.69M USD |
| Avg. Volume | 16.03M USD |
| Market Cap | 14.86M USD |
| Beta (5Y Monthly) | 2.084 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
APLT Valuation Measures
| Enterprise Value | 5.42M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.2575 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 14.862969 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 5.418 |
| Enterprise Value/EBITDA | -0.054 |
Trading Information
Applied Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.084 |
| 52-Week Change | -83.087% |
| S&P500 52-Week Change | 30.03% |
| 52 Week High | 1.5 USD |
| 52 Week Low | 0.09 USD |
| 50-Day Moving Average | 0.15 USD |
| 200-Day Moving Average | 0.46 USD |
APLT Share Statistics
| Avg. Volume (3 month) | 16.03M USD |
| Avg. Daily Volume (10-Days) | 7.74M USD |
| Shares Outstanding | 144.3M |
| Float | 119.83M |
| Short Ratio | 0.3 |
| % Held by Insiders | 5.49% |
| % Held by Institutions | 68.78% |
| Shares Short | 3.54M |
| Short % of Float | 2.46% |
| Short % of Shares Outstanding | 2.46% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | NaN |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | September 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1796.69% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -88.34% |
| Return on Equity (ttm) | -680.47% |
Income Statement
| Revenue (ttm) | 1M USD |
| Revenue Per Share (ttm) | 0.007 USD |
| Quarterly Revenue Growth (yoy) | 719.70% |
| Gross Profit (ttm) | -38056000 USD |
| EBITDA | -99611000 USD |
| Net Income Avi to Common (ttm) | -18138000 USD |
| Diluted EPS (ttm) | -0.1 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.95M USD |
| Total Cash Per Share (mrq) | 0.08 USD |
| Total Debt (mrq) | 2.5M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.962 |
| Book Value Per Share (mrq) | -0.004 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -86847000 USD |
| Levered Free Cash Flow (ttm) | -128157504 USD |
Profile of Applied Therapeutics
| Country | United States |
| State | NY |
| City | New York |
| Address | 545 Fifth Avenue |
| ZIP | 10017 |
| Phone | 212 220 9226 |
| Website | https://www.appliedtherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 28 |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. As of February 3, 2026, Applied Therapeutics, Inc. operates as a subsidiary of Cycle Group Holdings Limited.
Q&A For Applied Therapeutics Stock
What is a current APLT stock price?
Applied Therapeutics APLT stock price today per share is 0.1 USD.
How to purchase Applied Therapeutics stock?
You can buy APLT shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Applied Therapeutics?
The stock symbol or ticker of Applied Therapeutics is APLT.
Which industry does the Applied Therapeutics company belong to?
The Applied Therapeutics industry is Biotechnology.
How many shares does Applied Therapeutics have in circulation?
The max supply of Applied Therapeutics shares is 144.3M.
What is Applied Therapeutics Price to Earnings Ratio (PE Ratio)?
Applied Therapeutics PE Ratio is 0.00000000 now.
What was Applied Therapeutics earnings per share over the trailing 12 months (TTM)?
Applied Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Applied Therapeutics company belong to?
The Applied Therapeutics sector is Healthcare.
Applied Therapeutics APLT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}